Alignment Healthcare: The Drawdown I Told You To Wait For Has Arrived (Rating Upgrade)

Shailja Sharma 351 Followers Follow Summary Alignment Healthcare is upgraded from Hold to Buy after a 38% valuation-driven drawdown, despite continued operational outperformance. Q2 results delivered record-low medical benefits ratio, 31% membership growth, 48% adjusted EBITDA growth, and raised full-year guidance. ALHC now trades at 29x 2026 EPS and 0.5x forward sales, with a fair value in the low-to-mid $20s, implying 40%+ upside. I recommend building positions on weakness, as a soft Q3 guide and persistent skepticism suggest continued volatility despite improved risk-reward. Rawpixel/iStock via Getty Images Introduction In June I published a Hold on Alignment Healthcare , and the whole thesis was based on price, not the company itself. Alignment was a genuinely excellent Medicare Advantage operator growing membership above 30% with an improving margin profile, but This article was written by Shailja Sharma 351 Followers Follow I am a dedicated Finance professional with a Post-Graduate degree in Finance, specializing in independent market analysis and equity trading. My background is rooted in a deep understanding of macroeconomic trends and their direct impact on asset valuation. As an independent trader, I have developed a disciplined approach to the markets, focusing on capital preservation and a strict risk-to-reward ratio (typically 1:2 or higher). My areas of specialization include technical analysis, momentum trading, and fundamental research, particularly within the technology and financial sectors. On Seeking Alpha, I intend to provide readers with actionable, data-driven investment theses that bridge the gap between complex economic data and practical market execution. My sector focus primarily includes global tech and emerging market financials, where I utilize quantitative grounding to identify growth opportunities. My investing approach is a blend of "Growth At A Reasonable Price" (GARP) and momentum-based strategies, ensuring a rigorous margin of safety in every recommendation. I am motivated to write for Seeking Alpha to contribute high-quality, professional-grade analysis to a community of serious investors. By leveraging modern AI-enhanced research tools alongside traditional fundamental analysis, I aim to deliver clarity and strategic insights that help investors navigate volatile market cycles. My goal is to provide a fresh, expert perspective on market dynamics, helping readers make more informed and strategic investment decisions. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.